Pharming woos investors with high-tech Barnyard

Article Abstract:

Pharming NV, a Dutch-based biotech company, will offer four million new shares in a $50-million initial public offering (IPO) to be launched on Jun. 18, 1998. With Amsterdam, Netherlands-based investment bank Mees Pierson as lead manager, the IPO hopes to create a public float of roughly 30% of Pharming's shares outstanding. The IPO will provide Pharming with sufficient funds to complete clinical testing and, eventually, to roll out in late 199 its lead drug, which is used to treat a rare genetic affliction called Pompe's disease.

Comment:

Will offer 4 mil new shares in a $50-mil initial public offering to be launched on 6/18/98

Netherlands, Organizational history, Article, Pharming NV

---

Celltech to acquire Chiroscience

Article Abstract:

The acquisition of Cambridge, England-based Chiroscience Group PLC by Slough, England-based Celltech PLC, which has been valued 510.3 million in Eurodollars, has stunned the biotechnology industry. The acquisition bid would give Celltech a 52.4% stake in Chiroscience. Industry analysts have predicted that the merger will spur a new round of industry consolidation since the new company will have a dominant role in the biotechnology market.

Asset sales & divestitures, Research and Development in the Physical, Engineering, and Life Sciences, England, Chemistry, Mergers, acquisitions and divestments, Celltech Ltd., Chiroscience Group PLC

---

Roche's 2nd-quarter sales jumped 10% on demand for Xenical, other drugs

Article Abstract:

Roche Holding Ltd. announced that it posted a sharp improvement in its group sales for the second-quarter of 1999. The company's sales were helped by strong demand for its Xenical antiobesity drug, as well as by demand for other new drugs. For the quarter, Roche's sales increased 10% to 7 billion Swiss francs (4.37 billion euros). During the same period in 1998, the company posted 6.35 billion francs.

Comment:

Posts sharp improvement in group sales for second-quarter of 1999

Sales, profits & dividends, Switzerland, Finance, Abstract, Roche Holding Ltd.

Similar abstracts:

• Abstracts: Playing with perfection. CSBs revamped for younger demo. Package is key to Bits & Bites revival
• Abstracts: Intel is hit with antitrust charges. U.S. reveals witnesses for Intel trial. Intel earnings miss forecast, but improvement is seen
• Abstracts: GEC posts 7% increase in pretax profit. GKN's results buoy prospects for more deals. British Steel posts profit that beats analyst forecasts
• Abstracts: Gucci's quarterly sales rise despite Asia turmoil. Orangina rejects PepsiCo's new offer

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.